AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method for treating Alzheimer's disease comprising administering to a subject an effective amount of a pharmaceutical composition comprising an antibody that binds preferentially to amino acids 28-40 of $A\beta_{1-40}$ peptide (SEQ ID NO:1) and a ~~pharmaceutical~~ pharmaceutically acceptable carrier.

Claim 2 (original): The method of claim 1, wherein the antibody binds preferentially to an epitope that includes amino acid 39 and/or 40 of the $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 3 (original): The method of claim 1 or 2, wherein the antibody does not show significant cross-reactivity with $A\beta_{1-42}$ and $A\beta_{1-43}$ peptide.

Claim 4 (original): The method of claim 1, wherein the Fab fragment of the antibody binds to $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 5 (original): The method of claim 1, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 6 (original): The method of claim 2, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 7 (original): The method of claim 2, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 8 (original): The method of claim 1, wherein the antibody competitively inhibits binding of a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 to $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 9 (original): The method of claim 1, wherein the antibody binds to the same epitope to which a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 binds.

Claim 10 (currently amended): The method of claim 1, wherein the antibody is a monoclonal antibody.

Claim 11 (original): The method of claim 1, wherein the antibody is a humanized antibody.

Claim 12 (original): The method of claim 1, wherein the antibody is a human antibody.

Claim 13 (currently amended): A method of suppressing formation of amyloid plaques in a subject comprising administering to a subject an effective amount of a pharmaceutical composition comprising an antibody that binds preferentially to amino acids 28-40 of $A\beta_{1-40}$ peptide (SEQ ID NO:1) and a ~~pharmaceutical~~ pharmaceutically acceptable carrier.

Claim 14 (original): The method of claim 13, wherein the antibody binds preferentially to an epitope that includes amino acid 39 and/or 40 of the $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 15 (original): The method of claim 13, wherein the antibody does not show significant cross-reactivity with $A\beta_{1-42}$ and $A\beta_{1-43}$ peptide.

Claim 16 (original): The method of claim 13, wherein the Fab fragment of the antibody binds to $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 17 (original): The method of claim 13, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 18 (original): The method of claim 14, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 19 (original): The method of claim 14, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 20 (original): The method of claim 13, wherein the antibody competitively inhibits binding of a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 to $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 21 (original): The method of claim 13, wherein the antibody binds to the same epitope to which a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 binds.

Claim 22 (currently amended): The method of claim 13, wherein the antibody is a monoclonal antibody.

Claim 23 (original): The method of claim 13, wherein the antibody is a humanized antibody.

Claim 24 (original): The method of claim 13, wherein the antibody is a human antibody.

Claim 25 (original): The method of claim 13, wherein the amyloid plaques are in the brain of the subject.

Claim 26 (currently amended): A method of reducing amyloid plaques in a subject comprising administering to a subject an effective amount of a pharmaceutical composition comprising an antibody that binds preferentially to amino acids 28-40 of $A\beta_{1-40}$ peptide (SEQ ID NO:1) and a ~~pharmaceutical~~ pharmaceutically acceptable carrier.

Claim 27 (original): The method of claim 26, wherein the antibody binds preferentially to an epitope that includes amino acid 39 and/or 40 of the $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 28 (original): The method of claim 26, wherein the antibody does not show significant cross-reactivity with $A\beta_{1-42}$ and $A\beta_{1-43}$ peptide.

Claim 29 (original): The method of claim 26, wherein the Fab fragment of the antibody binds to $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 30 (original): The method of claim 26, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 31 (original): The method of claim 26, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 32 (original): The method of claim 27, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 33 (original): The method of claim 26, wherein the antibody competitively inhibits binding of a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 to $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 34 (original): The method of claim 26, wherein the antibody binds to the same epitope to which a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 binds.

Claim 35 (currently amended): The method of claim 26, wherein the antibody is a monoclonal antibody.

Claim 36 (original): The method of claim 26, wherein the antibody is a humanized antibody.

Claim 37 (original): The method of claim 26, wherein the antibody is a human antibody.

Claim 38 (original): The method of claim 26, wherein the amyloid plaques are in the brain of the subject.

Claim 39 (currently amended): A method of delaying development of a symptom associated with Alzheimer's disease in a subject having Alzheimer's disease comprising administering to the subject an effective amount of a pharmaceutical composition comprising an antibody that binds preferentially to amino acids 28-40 of $A\beta_{1-40}$ peptide (SEQ ID NO:1) and a ~~pharmaceutical~~ pharmaceutically acceptable carrier.

Claim 40 (original): The method of claim 39, wherein the antibody binds preferentially to an epitope that includes amino acid 39 and/or 40 of the $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 41 (original): The method of claim 39, wherein the antibody does not show significant cross-reactivity with $A\beta_{1-42}$ and $A\beta_{1-43}$ peptide.

Claim 42 (original): The method of claim 39, wherein the Fab fragment of the antibody binds to $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 43 (original): The method of claim 39, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 44 (original): The method of claim 40, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

Claim 45 (original): The method of claim 40, wherein the Fab fragment of the antibody binds $A\beta_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

Claim 46 (original): The method of claim 39, wherein the antibody competitively inhibits binding of a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 to $A\beta_{1-40}$ peptide (SEQ ID NO:1).

Claim 47 (original): The method of claim 39, wherein the antibody binds to the same epitope to which a monoclonal antibody comprising amino acid sequence of SEQ ID NO: 4 and 6 binds.

Claim 48 (currently amended): The method of claim 39, wherein the antibody is a monoclonal antibody.

Claim 49 (original): The method of claim 39, wherein the antibody is a humanized antibody.

Claim 50 (original): The method of claim 39, wherein the antibody is a human antibody.

Claim 51 (new): The method of claim 1, wherein the subject is a human.

Claim 52 (new): The method of claim 13, wherein the subject is a human.

Claim 53 (new): The method of claim 26, wherein the subject is a human.

Claim 54 (new): The method of claim 39, wherein the subject is a human.